India Pharma Outlook Team | Wednesday, 22 October 2025
Recently published data from the FLUNITY-HD Study in The Lancet illustrates that Efluelda provided significantly more protection against hospitalizations than standard-dose influenza vaccines in adults aged 65 and older.
The FLUNITY-HD study evaluated more than 466,000 older adults in Denmark and Spain, providing clear evidence of Efluelda's real-world effectiveness.
The vaccine provided 8.8% greater protection against pneumonia and influenza hospitalizations, reduced the incidence of cardio-respiratory hospitalizations by 6.3%, and decreased lab-confirmed influenza hospitalizations by 31.9%.
Also Read: India's Innovative Therapies Set Global Standard at Low Cost
Additionally, Efluelda afforded an extra 2.2% prevention against all-cause hospitalizations, which means that we could prevent a hospitalization for every 515 seniors vaccinated with a high-dose flu shot instead of a standard-dose flu shot.
Professor Tor Biering-Sørensen, lead investigator of the study FLUNITY-HD, believes the new findings are “important evidence that can redefine public health approaches and vaccination strategies” internationally. Co-investigator Professor Federico Martinon-Torres noted that the findings add further support to clinical confidence in high-dose vaccines for older adults, especially the vulnerable groups who are at a greater risk of flu complications.
Dr. Bogdana Coudsy, global head of medical at Sanofi, stated that fewer flu hospitalizations not only safeguard senior adults' well-being, but also limit costs to the healthcare system and lessen the burden to the healthcare system itself.
The high-dose influenza vaccine Efluelda has demonstrated, to date, 15 years of clinical evidence spread over 45 million older adults, and continues to be a viable option to assist in the protection of aging populations, while simultaneously being a risk-reduction for an important public health issue globally.
.jpg)
